A detailed history of Avidity Partners Management LP transactions in Ac Immune Sa stock. As of the latest transaction made, Avidity Partners Management LP holds 825,000 shares of ACIU stock, worth $2.48 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares
825,000
Previous 4,470,000 81.54%
Holding current value
$2.48 Million
Previous $13.2 Million 75.13%
% of portfolio
0.16%
Previous 0.51%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$2.29 - $4.87 $8.35 Million - $17.8 Million
-3,645,000 Reduced 81.54%
825,000 $3.29 Million
Q1 2024

May 15, 2024

BUY
$2.66 - $4.87 $2,447 - $4,480
920 Added 0.02%
4,470,000 $13.2 Million
Q4 2023

Feb 14, 2024

BUY
$2.46 - $5.0 $3.69 Million - $7.5 Million
1,499,280 Added 50.48%
4,469,080 $22.3 Million
Q3 2023

Nov 14, 2023

BUY
$2.77 - $3.38 $184,265 - $224,844
66,522 Added 2.29%
2,969,800 $8.46 Million
Q2 2023

Aug 14, 2023

BUY
$1.85 - $3.4 $4.77 Million - $8.76 Million
2,577,878 Added 792.22%
2,903,278 $8.59 Million
Q4 2022

Feb 14, 2023

BUY
$1.72 - $3.12 $86,901 - $157,634
50,524 Added 18.38%
325,400 $663,000
Q3 2022

Nov 14, 2022

BUY
$2.4 - $3.64 $659,702 - $1 Million
274,876 New
274,876 $869,000
Q4 2021

Feb 14, 2022

SELL
$4.83 - $7.56 $8.4 Million - $13.2 Million
-1,739,600 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$6.2 - $8.34 $964,720 - $1.3 Million
155,600 Added 9.82%
1,739,600 $11.7 Million
Q2 2021

Aug 16, 2021

BUY
$6.04 - $8.37 $9.57 Million - $13.3 Million
1,584,000 New
1,584,000 $12.6 Million
Q4 2020

Feb 16, 2021

SELL
$4.47 - $5.58 $6.93 Million - $8.65 Million
-1,550,000 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$4.78 - $9.06 $7.41 Million - $14 Million
1,550,000 New
1,550,000 $7.56 Million

Others Institutions Holding ACIU

About AC Immune SA


  • Ticker ACIU
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,413,504
  • Market Cap $250M
  • Description
  • AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...
More about ACIU
Track This Portfolio

Track Avidity Partners Management LP Portfolio

Follow Avidity Partners Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Avidity Partners Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Avidity Partners Management LP with notifications on news.